Heat Biologics HTBX Stock News

Heat Biologics Inc (NASDAQ: HTBX) is flying in the market this morning, trading on gains of around 75% early on. While the company hasn’t issued a press release, there is an SEC filing hitting the tape that’s causing all of the excitement. Apparently, the company is working its way toward a coronavirus-related patent. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

HTBX Stock Is Flying On Coronavirus Patent Application

As mentioned above, Heat Biologics didn’t issue any news via press release this morning, but it didn’t have to. The company caused all of the excitement it needed with a simple SEC filing.

In the filing, HTBX said that it has filed a new provisional patent application. In particular, the application applies the company’s immune system activating technology for treating and preventing infection with SARS-COV-2 virus, the virus that causes COVID-19.

As we’ve seen very clearly, the market has been a rough place to be. That is, unless you’re working in the coronavirus space. With fears that the coronavirus will lead to production delays, economic issues, and various other uncertainties, investors have been ditching most stocks and putting their money in safe havens and coronavirus-related securities.

So, for HTBX, a company that generally focused on the treatment of cancer, to shift toward the treatment and prevention of the Wuhan coronavirus, this is big news.

Why This News Is So Important

There are a few reasons that the news surrounding Heat Biologics is sending the stock for the top. Here’s how I see it:

  • COVID-19 – Number one is the issue in and of itself, COVID-19. As the virus continues to spread, investors see opportunities in vaccines and treatments. So, with Heat Biologics announcing that it’s getting into the space, investors are excited.
  • Vaccine & Treatment – The immune system boosting technology at HTBX is very interesting. In fact, it’s possible that this technology could lead to both, the creation of a vaccine, and the creation of a treatment. While several companies are working to create a vaccine, the only other company that has publicly announced that it is working on a treatment is AIM ImmunoTech (NYSEAMERICAN:AIM). So, the race is on and the winner of the race to a treatment could lead to massive profits for the winner.
  • Fast Manufacturing – Like iBio (NYSEAMERICAN: IBIO), HTBX has the ability to manufacture its vaccines and treatments increadibly quickly. This gives the company a key competitive advantage in the marketplace. Moreover, after IBIO ran to gains of more than 900%, investors are looking for the next similar opportunity and this seems to be it.

The bottom line here is that HTBX hit the nail on the head when it decided to use its technology to fight COVID-19. Due to the serious medical need in this spreading epidemic, the revenue opportunity could be massive if the company does successfully find a way to vaccinate against or treat the virus. All in all, this could be a massive opportunity for investors.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


1 COMMENT

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.